Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion by GBIResearch

VIEWS: 10 PAGES: 198

More Info
									          Cytotoxic Therapies Market to 2017 - Launch of Next
          Generation Camptothecin Analogues Will Help Offset
                 Revenue Loss due to Generic Erosion
 Reference Code: GBIHC169MR                                                                                          Publication Date: April 2012


                                   The Cytotoxic Therapies Market is Set to Experience Marginal Decline in the Forecast Period
   The cytotoxic therapies
   market for the eight             Cytotoxic Therapies Market, Global, Revenue Forecasts ($bn), 2002-2017
   oncology indications is set
   to decline by (0.1%) in the                           12
   forecast period.
                                                                                                      CAGR (2010-2017): (0.1%)


                                                         10
                                                              CAGR (2002-2010): 5.8%



                                                          8
                                         Revenue ($bn)




                                                          6




                                                          4




                                                          2




                                                          0
                                                                2002                           2010                              2017


                                    Source: GBI Research, Company Annual Reports, SEER, Globocan, National Cancer Institute




                                   The cytotoxic therapies market accounted for $6.5 billion in revenue in 2002 from its eight major
                                   indications, which include breast cancer, cervical cancer, colorectal cancer, head and neck cancer,
                                   non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer and prostate cancer. From
                                   2002, the market grew at a compound annual growth rate (CAGR) of 5.8%, to $10.1 billion in 2010,
                                   and it is estimated to decline marginally at (0.1%) during the forecast period to produce revenues of
                                   $10.1 billion in 2017. The average annual cost of therapy for cytotoxic therapies is estimated to
                                   decrease moderately over the forecast period, and is expected to reach an approximate value of
                                   $7,667 by 2017. Overall, the cytotoxic therapies market value will decrease moderately between
                                   2010 and 2017.




Cytotoxic Therapies Market to 2017 - Launch of Next                                                              GBIHC169MR / Published APR 2012
Generation Camptothecin Analogues Will Help Offset Revenue                                                                                     Page 1
Loss due to Generic Erosion                                                 © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                            reproduced, shared or resold in any form
                                   Increasing Acceptance of Combinations of Cytotoxic Medicines with Monoclonal Antibodies
                                   will counter the Use of Generics
                                   The therapeutic capabilities of biologics in controlling and treating oncology complications have led
                                   to their widespread use and popularity amongst patients and prescribers alike. This has convinced
                                   pharmaceutical manufacturers to commence label extensions of their present portfolio of biologics
                                   for multiple oncology complications, even in combination with cytotoxic medicines. This will act as a
                                   support to the continued use of cytotoxic drugs, even though safety issues exist. In addition,
                                   industry trends suggest that pharmaceutical companies are more interested in researching and
                                   developing novel targeted therapies and biologics rather than discovering novel cytotoxic drugs, as
                                   these continue to have major safety hurdles. Safety is an important measure, not only during
                                   approval but also when determining reimbursement lists. Reimbursements for almost all
                                   therapeutic areas are under severe pressure. Taken together, the industry and environmental
                                   trends suggest that the cytotoxic medicines market is likely to see a slow increase in market value
                                   within the next few years.
                                   Patent Expiration of Major Cytotoxic Brands such as Taxotere and Gemzar will Exert
                                   Downward Pressure on the Cytotoxic Therapies Market
                                   Major cytotoxic brands such as Taxotere (docetaxel) by Sanofi and Gemzar (gemcitabine) by Eli
                                   Lilly have been blockbuster brands. While Taxotere achieved sales of $1.2 billion in 2011, Gemzar
                                   recorded global sales of $452.1m in the same year. Other brands such as Alimta (pemetrexed) and
                                   Xeloda (capecitabine) have also crossed the billion dollar mark in sales. However, these drugs are
                                   set to lose their patent protection in coming years, which will allow the entry of generics. Combined
                                   with the fact that the current pipeline of development for cytotoxic medicines also looks weak, this
                                   will result in an eventual decline of the cytotoxic therapies market. Acceptance of generics by
                                   governments in Europe and the US, combined with the increase in the prescription population, will
                                   ensure that the cytotoxic therapies market declines only marginally up to 2017.




Cytotoxic Therapies Market to 2017 - Launch of Next                                                       GBIHC169MR / Published APR 2012
Generation Camptothecin Analogues Will Help Offset Revenue                                                                              Page 2
Loss due to Generic Erosion                                          © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                     reproduced, shared or resold in any form
                                   1         Table of Contents
                                   1   Table of Contents ........................................................................................................................ 3
                                       1.1    List of Tables..................................................................................................................... 7
                                       1.2    List of Figures ................................................................................................................. 11
                                   2   Cytotoxic Therapies Market to 2017 - Introduction .................................................................... 14
                                       2.1    GBI Research Report Guidance ..................................................................................... 15
                                   3   Cytotoxic Therapies Market to 2017 - Market Overview ............................................................ 16
                                       3.1    Introduction ..................................................................................................................... 16
                                          3.1.1    Revenue .................................................................................................................. 16
                                          3.1.2    Annual Cost of Therapy ........................................................................................... 19
                                          3.1.3    Treatment Usage Pattern ........................................................................................ 20
                                       3.2    Drivers and Barriers for the Global Cytotoxic Therapies Market ..................................... 22
                                          3.2.1    Drivers for the Global Cytotoxic Therapies Market .................................................. 22
                                          3.2.2    Barriers for the Global Cytotoxic Therapies Market ................................................. 23
                                   4   Cytotoxic Therapies Market to 2017 - Geographical Landscape ............................................... 24
                                       4.1    Geographical Segmentation............................................................................................ 24
                                       4.2    The US ............................................................................................................................ 26
                                          4.2.1    Revenue .................................................................................................................. 26
                                          4.2.2    Annual Cost of Therapy ........................................................................................... 27
                                          4.2.3    Treatment Usage Pattern ........................................................................................ 28
                                          4.2.4    Drivers and Barriers for the Cytotoxic Therapies Market in the US ......................... 30
                                       4.3    Top Five Countries of Europe ......................................................................................... 32
                                          4.3.1    Revenue .................................................................................................................. 32
                                          4.3.2    Annual Cost of Therapy ........................................................................................... 33
                                          4.3.3    Treatment Usage Pattern ........................................................................................ 34
                                          4.3.4    Drivers and Barriers for the Cytotoxic Therapies Market in the Top Five Countries of
                                                   Europe ..................................................................................................................... 36
                                       4.4    Japan .............................................................................................................................. 38
                                          4.4.1    Revenue .................................................................................................................. 38
                                          4.4.2    Annual Cost of Therapy ........................................................................................... 39
                                          4.4.3    Treatment Usage Pattern ........................................................................................ 40
                                          4.4.4    Drivers and Barriers for the Cytotoxic Therapies Market in Japan........................... 42
                                   5   Cytotoxic Therapies Market to 2017 - Therapeutic Landscape.................................................. 44
                                       5.1    Breast Cancer ................................................................................................................. 44
                                          5.1.1    Introduction .............................................................................................................. 44
                                          5.1.2    Survival Rates by Stage .......................................................................................... 46
                                          5.1.3    Symptoms................................................................................................................ 46
                                          5.1.4    Treatment Flow........................................................................................................ 47
                                          5.1.5    Revenue .................................................................................................................. 50
                                          5.1.6    Annual Cost of Therapy ........................................................................................... 53
                                          5.1.7    Treatment Usage Pattern ........................................................................................ 54
                                          5.1.8    Drivers and Barriers................................................................................................. 56
                                       5.2    Cervical Cancer .............................................................................................................. 57
                                          5.2.1    Introduction .............................................................................................................. 57
                                          5.2.2    Survival Rates ......................................................................................................... 58
                                          5.2.3    Symptoms................................................................................................................ 59
                                          5.2.4    Treatment Flow........................................................................................................ 59
                                          5.2.5    Revenue .................................................................................................................. 60
                                          5.2.6    Annual Cost of Therapy ........................................................................................... 63
                                          5.2.7    Treatment Usage Pattern ........................................................................................ 64
                                          5.2.8    Drivers and Barriers................................................................................................. 66
                                       5.3    Colorectal Cancer ........................................................................................................... 67
                                          5.3.1    Introduction .............................................................................................................. 67
                                          5.3.2    Survival Rates by Stage .......................................................................................... 68


Cytotoxic Therapies Market to 2017 - Launch of Next                                                                     GBIHC169MR / Published APR 2012
Generation Camptothecin Analogues Will Help Offset Revenue                                                                                            Page 3
Loss due to Generic Erosion                                                        © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                   reproduced, shared or resold in any form
                                        5.3.3    Symptoms................................................................................................................ 68
                                        5.3.4    Treatment Flow........................................................................................................ 69
                                        5.3.5    Revenue .................................................................................................................. 72
                                        5.3.6    Annual Cost of Therapy ........................................................................................... 75
                                        5.3.7    Treatment Usage Pattern ........................................................................................ 76
                                        5.3.8    Drivers and Barriers................................................................................................. 78
                                     5.4    Head and Neck Cancer................................................................................................... 79
                                        5.4.1    Introduction .............................................................................................................. 79
                                        5.4.2    Survival Rates ......................................................................................................... 80
                                        5.4.3    Symptoms................................................................................................................ 80
                                        5.4.4    Treatment Flow........................................................................................................ 81
                                        5.4.5    Revenue .................................................................................................................. 82
                                        5.4.6    Annual Cost of Therapy ........................................................................................... 86
                                        5.4.7    Treatment Usage Pattern ........................................................................................ 87
                                        5.4.8    Drivers and Barriers................................................................................................. 89
                                     5.5    Non-Hodgkin Lymphoma ................................................................................................ 90
                                        5.5.1    Introduction .............................................................................................................. 90
                                        5.5.2    Survival Rates by Stage .......................................................................................... 91
                                        5.5.3    Symptoms................................................................................................................ 91
                                        5.5.4    Treatment Flow........................................................................................................ 92
                                        5.5.5    Revenue .................................................................................................................. 93
                                        5.5.6    Annual Cost of Therapy ........................................................................................... 96
                                        5.5.7    Treatment Usage Pattern ........................................................................................ 97
                                        5.5.8    Drivers and Barriers................................................................................................. 99
                                     5.6    Non-Small Cell Lung Cancer (NSCLC) ......................................................................... 100
                                        5.6.1    Introduction ............................................................................................................ 100
                                        5.6.2    Survival Rates by Stage ........................................................................................ 101
                                        5.6.3    Symptoms.............................................................................................................. 101
                                        5.6.4    Treatment Flow...................................................................................................... 102
                                        5.6.5    Revenue ................................................................................................................ 104
                                        5.6.6    Annual Cost of Therapy ......................................................................................... 107
                                        5.6.7    Treatment Usage Pattern ...................................................................................... 108
                                        5.6.8    Drivers and Barriers............................................................................................... 110
                                     5.7    Ovarian Cancer ............................................................................................................. 111
                                        5.7.1    Introduction ............................................................................................................ 111
                                        5.7.2    Survival Rates ....................................................................................................... 111
                                        5.7.3    Symptoms.............................................................................................................. 112
                                        5.7.4    Treatment Flow...................................................................................................... 112
                                        5.7.5    Revenue ................................................................................................................ 113
                                        5.7.6    Annual Cost of Therapy ......................................................................................... 116
                                        5.7.7    Treatment Usage Pattern ...................................................................................... 117
                                        5.7.8    Drivers and Barriers............................................................................................... 119
                                     5.8    Prostate Cancer ............................................................................................................ 120
                                        5.8.1    Introduction ............................................................................................................ 120
                                        5.8.2    Survival Rates ....................................................................................................... 121
                                        5.8.3    Symptoms.............................................................................................................. 121
                                        5.8.4    Treatment Flow...................................................................................................... 122
                                        5.8.5    Revenue ................................................................................................................ 123
                                        5.8.6    Annual Cost of Therapy ......................................................................................... 127
                                        5.8.7    Treatment Usage Pattern ...................................................................................... 128
                                        5.8.8    Drivers and Barriers............................................................................................... 130
                                   6 Cytotoxic Therapies Market to 2017 - Pipeline Analysis .......................................................... 131
                                     6.1    Introduction ................................................................................................................... 131
                                     6.2    Cytotoxic Therapies Market - Pipeline Assessment by Indication ................................. 133
                                        6.2.1    Breast Cancer........................................................................................................ 133

Cytotoxic Therapies Market to 2017 - Launch of Next                                                                    GBIHC169MR / Published APR 2012
Generation Camptothecin Analogues Will Help Offset Revenue                                                                                           Page 4
Loss due to Generic Erosion                                                       © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                  reproduced, shared or resold in any form
                                        6.2.2     Cervical Cancer ..................................................................................................... 137
                                        6.2.3     Colorectal Cancer .................................................................................................. 138
                                        6.2.4     Head and Neck Cancer ......................................................................................... 143
                                        6.2.5     Non-Hodgkin Lymphoma ....................................................................................... 146
                                        6.2.6     Non-Small Cell Lung Cancer ................................................................................. 149
                                        6.2.7     Ovarian Cancer ..................................................................................................... 153
                                        6.2.8     Prostate Cancer..................................................................................................... 159
                                     6.3    Profiles of Promising Molecules in the Cytotoxic Therapies Market .............................. 162
                                        6.3.1     Eniluracil (ADH300004) ......................................................................................... 162
                                        6.3.2     Karenitecin............................................................................................................. 163
                                        6.3.3     Vintafolide (EC145) ............................................................................................... 164
                                        6.3.4     Tavocept................................................................................................................ 165
                                   7 Cytotoxic Therapies Market to 2017 - Competitive Lanscape ................................................. 167
                                     7.1    Sanofi ............................................................................................................................ 167
                                        7.1.1     Company Overview ............................................................................................... 167
                                        7.1.2     Marketed Products ................................................................................................ 168
                                        7.1.3     SWOT Analysis ..................................................................................................... 168
                                     7.2    Eli Lilly & Company ....................................................................................................... 169
                                        7.2.1     Company Overview ............................................................................................... 169
                                        7.2.2     Marketed Products ................................................................................................ 170
                                        7.2.3     SWOT Analysis ..................................................................................................... 171
                                     7.3    Takeda Pharmaceutical Company Ltd. ......................................................................... 172
                                        7.3.1     Company Overview ............................................................................................... 172
                                        7.3.2     Marketed Products ................................................................................................ 173
                                        7.3.3     SWOT Analysis ..................................................................................................... 173
                                     7.4    F. Hoffmann-La Roche Ltd. ........................................................................................... 174
                                        7.4.1     Company Overview ............................................................................................... 174
                                        7.4.2     Marketed Products ................................................................................................ 175
                                        7.4.3     SWOT Analysis ..................................................................................................... 175
                                   8 Cytotoxic Therapies Market to 2017 - Strategic Consolidations .............................................. 176
                                     8.1    Deals by Type ............................................................................................................... 176
                                     8.2    Deals by Indication........................................................................................................ 177
                                     8.3    Mergers and Acquisitions .............................................................................................. 178
                                        8.3.1     Segmentation by Year ........................................................................................... 178
                                        8.3.2     Segmentation by Value ......................................................................................... 179
                                        8.3.3     Segmentation by Geography ................................................................................. 180
                                        8.3.4     Major Merger and Acquisition Deals ...................................................................... 180
                                     8.4    Co-Development Deals ................................................................................................. 181
                                        8.4.1     Segmentation by Year ........................................................................................... 182
                                        8.4.2     Segmentation by Geography ................................................................................. 183
                                        8.4.3     Major Co-Development Deals................................................................................ 184
                                     8.5    Licensing Deals............................................................................................................. 185
                                        8.5.1     Segmentation by Year ........................................................................................... 186
                                        8.5.2     Segmentation by Value ......................................................................................... 187
                                        8.5.3     Segmentation by Geography ................................................................................. 188
                                        8.5.4     Major Licensing Deals ........................................................................................... 190
                                   9 Cytotoxic Therapies Market to 2017 - Appendix ...................................................................... 191
                                     9.1    Market Definitions ......................................................................................................... 191
                                     9.2    Abbreviations ................................................................................................................ 191
                                     9.3    Sources ......................................................................................................................... 193
                                     9.4    Research Methodology ................................................................................................. 194
                                        9.4.1     Coverage ............................................................................................................... 194
                                        9.4.2     Secondary Research ............................................................................................. 194
                                        9.4.3     Primary Research .................................................................................................. 194
                                        9.4.4     Therapeutic Landscape ......................................................................................... 195

Cytotoxic Therapies Market to 2017 - Launch of Next                                                                     GBIHC169MR / Published APR 2012
Generation Camptothecin Analogues Will Help Offset Revenue                                                                                            Page 5
Loss due to Generic Erosion                                                        © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                   reproduced, shared or resold in any form
                                         9.4.5    Market Size by Geography .................................................................................... 197
                                         9.4.6    Geographical Landscape....................................................................................... 197
                                         9.4.7    Pipeline Analysis ................................................................................................... 198
                                         9.4.8    Competitive Landscape ......................................................................................... 198
                                         9.4.9    Expert Panel Validation ......................................................................................... 198
                                      9.5    Contact Us .................................................................................................................... 198
                                      9.6    Disclaimer ..................................................................................................................... 198




Cytotoxic Therapies Market to 2017 - Launch of Next                                                                    GBIHC169MR / Published APR 2012
Generation Camptothecin Analogues Will Help Offset Revenue                                                                                           Page 6
Loss due to Generic Erosion                                                       © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                  reproduced, shared or resold in any form
                                   1.1    List of Tables
                                   Table 1:    Cytotoxic Therapies Market, Global, Revenue ($bn), 2002-2010................................... 16
                                   Table 2:    Cytotoxic Therapies Market, Global, Revenue Forecasts ($bn), 2010-2017 .................. 16
                                   Table 3:    Cytotoxic Therapies Market, Global, Annual Cost of Therapy ($), 2002-2010 ............... 19
                                   Table 4:    Cytotoxic Therapies Market, Global, Annual Cost of Therapy ($), 2010-2017 ............... 19
                                   Table 5:    Cytotoxic Therapies Market, Global, Treatment Usage Pattern, Population (‘000), 2002-
                                               2010 ............................................................................................................................... 20
                                   Table 6:    Cytotoxic Therapies Market, Global, Treatment Usage Pattern, Population (‘000), 2010-
                                               2017 ............................................................................................................................... 21
                                   Table 7:    Cytotoxic Therapies Market, Global, Geographical Segmentation ($m), 2002-2010...... 24
                                   Table 8:    Cytotoxic Therapies Market, Global, Geographical Segmentation ($m), 2010-2017...... 24
                                   Table 9:    Cytotoxic Therapies Market, The US, Revenue ($bn), 2002-2010 ................................. 26
                                   Table 10:   Cytotoxic Therapies Market, The US, Revenue Forecasts ($bn), 2010-2017 ................ 26
                                   Table 11:   Cytotoxic Therapies Market, The US, Annual Cost of Therapy ($), 2002-2010 ............. 27
                                   Table 12:   Cytotoxic Therapies Market, The US, Annual Cost of Therapy ($), 2010-2017 ............. 27
                                   Table 13:   Cytotoxic Therapies Market, The US, Treatment Usage Pattern, Population (‘000), 2002-
                                               2010 ............................................................................................................................... 28
                                   Table 14:   Cytotoxic Therapies Market, The US, Treatment Usage Pattern, Population (‘000), 2010-
                                               2017 ............................................................................................................................... 29
                                   Table 15:   Cytotoxic Therapies Market, Top Five Countries of Europe, Revenue ($m), 2002-201032
                                   Table 16:   Cytotoxic Therapies Market, Top Five Countries of Europe, Revenue Forecasts ($m),
                                               2010-2017 ...................................................................................................................... 32
                                   Table 17:   Cytotoxic Therapies Market, Top Five Countries of Europe, Annual Cost of Therapy ($),
                                               2002-2010 ...................................................................................................................... 33
                                   Table 18:   Cytotoxic Therapies Market, Top Five Countries of Europe, Annual Cost of Therapy ($),
                                               2010-2017 ...................................................................................................................... 33
                                   Table 19:   Cytotoxic Therapies Market, Top Five Countries of Europe, Treatment Usage Pattern,
                                               Population (‘000), 2002-2010 ......................................................................................... 34
                                   Table 20:   Cytotoxic Therapies Market, Top Five Countries of Europe, Treatment Usage Pattern,
                                               Population (‘000), 2010-2017 ......................................................................................... 35
                                   Table 21:   Cytotoxic Therapies Market, Japan, Revenue ($m), 2002-2010 .................................... 38
                                   Table 22:   Cytotoxic Therapies Market, Japan, Revenue Forecasts ($m), 2010-2017 ................... 38
                                   Table 23:   Cytotoxic Therapies Market, Japan, Annual Cost of Therapy ($), 2002-2010 ................ 39
                                   Table 24:   Cytotoxic Therapies Market, Japan, Annual Cost of Therapy ($), 2010-2017 ................ 39
                                   Table 25:   Cytotoxic Therapies Market, Japan, Treatment Usage Pattern, Population (‘000), 2002-
                                               2010 ............................................................................................................................... 40
                                   Table 26:   Cytotoxic Therapies Market, Japan, Treatment Usage Pattern, Population (‘000), 2010-
                                               2017 ............................................................................................................................... 41
                                   Table 27:   Cytotoxic Therapies Market, Global, Breast Cancer, Cancer Categorized by Disease
                                               Stage, 2011.................................................................................................................... 44
                                   Table 28:   Cytotoxic Therapies Market, Global, Breast Cancer, Stage Distribution and Survival For
                                               Patients in the US (%), 2001-2007 ................................................................................. 46
                                   Table 29:   Cytotoxic Therapies Market, Global, Breast Cancer, Revenue ($m), 2002-2010 ........... 50
                                   Table 30:   Cytotoxic Therapies Market, Global, Breast Cancer, Revenue Forecasts ($m), 2010-
                                               2017 ............................................................................................................................... 50
                                   Table 31:   Cytotoxic Therapies Market, Global, Breast Cancer, Geographical Segmentation ($m),
                                               2002-2010 ...................................................................................................................... 51
                                   Table 32:   Cytotoxic Therapies Market, Global, Breast Cancer, Geographical Segmentation ($m),
                                               2010-2017 ...................................................................................................................... 52
                                   Table 33:   Cytotoxic Therapies Market, Global, Breast Cancer, Annual Cost of Therapy ($), 2002-
                                               2010 ............................................................................................................................... 53
                                   Table 34:   Cytotoxic Therapies Market, Global, Breast Cancer, Annual Cost of Therapy ($), 2010-
                                               2017 ............................................................................................................................... 53
                                   Table 35:   Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Usage Pattern,
                                               Population (‘000), 2002-2010 ......................................................................................... 54
                                   Table 36:   Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Usage Pattern,
                                               Population (‘000), 2010-2017 ......................................................................................... 55
                                   Table 37:   Cytotoxic Therapies Market, Global, Cervical Cancer, Clinical Staging, 2011 ............... 58
                                   Table 38:   Cytotoxic Therapies Market, Global, Cervical Cancer, Stage Distribution and Survival
                                               For Patients in the US (%), 2001-2007 .......................................................................... 58
                                   Table 39:   Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Flow ......................... 59
                                   Table 40:   Cytotoxic Therapies Market, Global, Cervical Cancer, Revenue ($m), 2002-2010 ........ 60

Cytotoxic Therapies Market to 2017 - Launch of Next                                                                   GBIHC169MR / Published APR 2012
Generation Camptothecin Analogues Will Help Offset Revenue                                                                                          Page 7
Loss due to Generic Erosion                                                      © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                 reproduced, shared or resold in any form
                                   Table 41: Cytotoxic Therapies Market, Global, Cervical Cancer, Revenue Forecast ($m), 2010-
                                             2017 ............................................................................................................................... 60
                                   Table 42: Cytotoxic Therapies Market, Global, Cervical Cancer, Geographical Segmentation ($m),
                                             2002-2010 ...................................................................................................................... 61
                                   Table 43: Cytotoxic Therapies Market, Global, Cervical Cancer, Geographical Segmentation ($m),
                                             2010-2017 ...................................................................................................................... 62
                                   Table 44: Cytotoxic Therapies Market, Global, Cervical Cancer, Annual Cost of Therapy ($), 2002-
                                             2010 ............................................................................................................................... 63
                                   Table 45: Cytotoxic Therapies Market, Global, Cervical Cancer, Annual Cost of Therapy ($), 2010-
                                             2017 ............................................................................................................................... 63
                                   Table 46: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Usage Pattern,
                                             Population (‘000), 2002-2010 ......................................................................................... 64
                                   Table 47: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Usage Pattern,
                                             Population (‘000), 2010-2017 ......................................................................................... 65
                                   Table 48: Cytotoxic Therapies Market, Global, Colorectal Cancer, Cancer Categorized by Disease
                                             Stage.............................................................................................................................. 68
                                   Table 49: Cytotoxic Therapies Market, Global, Colorectal Cancer, Stage Distribution and Five-Year
                                             Relative Survival by Stage at Diagnosis for Patients in the US (%), 2001-2007 ............ 68
                                   Table 50: Cytotoxic Therapies Market, Global, Colorectal Cancer, Revenue ($bn), 2002-2010 .... 72
                                   Table 51: Cytotoxic Therapies Market, Global, Colorectal Cancer, Revenue Forecasts ($bn), 2010-
                                             2017 ............................................................................................................................... 72
                                   Table 52: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation
                                             ($m), 2002-2010............................................................................................................. 73
                                   Table 53: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation
                                             ($m), 2010-2017............................................................................................................. 74
                                   Table 54: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($),
                                             2002-2010 ...................................................................................................................... 75
                                   Table 55: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($),
                                             2010-2017 ...................................................................................................................... 75
                                   Table 56: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Usage Pattern,
                                             Population (‘000), 2002-2010 ......................................................................................... 77
                                   Table 57: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Usage Pattern,
                                             Population (‘000), 2010-2017 ......................................................................................... 77
                                   Table 58: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Staging, 2011 ................ 79
                                   Table 59: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Stage Distribution and
                                             Survival For Patients in the US (%), 1998-2001 ............................................................. 80
                                   Table 60: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Revenue ($m), 2002-2010
                                             ....................................................................................................................................... 82
                                   Table 61: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Revenue Forecasts ($m),
                                             2010-2017 ...................................................................................................................... 82
                                   Table 62: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical
                                             Segmentation ($m), 2002-2010 ..................................................................................... 84
                                   Table 63: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical
                                             Segmentation ($m), 2010-2017 ..................................................................................... 84
                                   Table 64: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy
                                             ($), 2002-2010................................................................................................................ 86
                                   Table 65: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy
                                             ($), 2010-2017................................................................................................................ 86
                                   Table 66: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Usage Pattern,
                                             Population (‘000), 2002-2010 ......................................................................................... 87
                                   Table 67: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Usage Pattern,
                                             Population (‘000), 2010-2017 ......................................................................................... 88
                                   Table 68: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Cancer Categorized by
                                             Disease Stage ................................................................................................................ 90
                                   Table 69: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Stage Distribution and 5-
                                             Year Survival Rates by Stage at Diagnosis for Patients in the US (%), 2001-2007 ....... 91
                                   Table 70: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Revenue ($m), 2002-
                                             2010 ............................................................................................................................... 93
                                   Table 71: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Revenue Forecasts ($m),
                                             2010-2017 ...................................................................................................................... 93
                                   Table 72: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical
                                             Segmentation ($m), 2002-2010 ..................................................................................... 94


Cytotoxic Therapies Market to 2017 - Launch of Next                                                                      GBIHC169MR / Published APR 2012
Generation Camptothecin Analogues Will Help Offset Revenue                                                                                             Page 8
Loss due to Generic Erosion                                                         © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                    reproduced, shared or resold in any form
                                   Table 73: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical
                                              Segmentation ($m), 2010-2017 ..................................................................................... 95
                                   Table 74: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy
                                              ($), 2002-2010................................................................................................................ 96
                                   Table 75: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy
                                              ($), 2010-2017................................................................................................................ 96
                                   Table 76: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Usage
                                              Pattern, Population (‘000), 2002-2010 ........................................................................... 97
                                   Table 77: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Usage
                                              Pattern, Population (‘000), 2010-2017 ........................................................................... 98
                                   Table 78: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Cancer Categorized
                                              by Disease Stage ......................................................................................................... 100
                                   Table 79: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Stage Distribution
                                              and Survival for Lung Cancer Patients in the US (%), 2000-2007................................ 101
                                   Table 80: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Revenue ($m), 2002-
                                              2010 ............................................................................................................................. 104
                                   Table 81: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Revenue Forecasts
                                              ($m), 2010-2017........................................................................................................... 104
                                   Table 82: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical
                                              Segmentation ($m), 2002-2010 ................................................................................... 105
                                   Table 83: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical
                                              Segmentation ($m), 2010-2017 ................................................................................... 106
                                   Table 84: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of
                                              Therapy ($), 2002-2010 ............................................................................................... 107
                                   Table 85: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of
                                              Therapy ($), 2010-2017 ............................................................................................... 107
                                   Table 86: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Usage
                                              Pattern, Population (‘000), 2002-2010 ......................................................................... 108
                                   Table 87: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Usage
                                              Pattern, Population (‘000), 2010-2017 ......................................................................... 109
                                   Table 88: Cytotoxic Therapies Market, Global, Ovarian Cancer, Surgical Staging, 2011 ............ 111
                                   Table 89: Cytotoxic Therapies Market, Global, Ovarian Cancer, Stage Distribution and Survival for
                                              Patients in the US (%), 2001-2007 ............................................................................... 111
                                   Table 90: Cytotoxic Therapies Market, Global, Ovarian Cancer, Post-Operative Treatment, 2011
                                              ..................................................................................................................................... 112
 
								
To top